Top News

Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI

Younger Breast Cancer Patients at Higher Risk for Osteoporosis

Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified

Gly101Val Mutation Directly Causes Resistance to Venetoclax

Can Treatments for Childhood ALL Alter the Gut Microbiome?

Olaratumab May Be Safe and Effective in Patients With Advanced Soft Tissue Sarcoma

Next-Generation Sequencing May Benefit Some Patients With Sarcoma

Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma

Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC

Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer

more »

FEATURED

Lower-Dose, Shorter-Duration Chemotherapy

Lower doses and shorter treatment regimens have the potential to reduce both physical and financial toxicity for patients.

The Evolution of CAR-T

"CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses," according to Dr Michel Sadelin.

Selinexor Trials for Multiple Myeloma

XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.

Ask the Experts: NSCLC

Cancer Therapy Advisor asked 2 experts to weigh in on recommended treatment modalities for patients with non-small cell lung cancer.

Ask the Experts: STS Clinical Insights

Cancer Therapy Advisor asked 2 experts to weigh in on the latest clinical insights into soft tissue sarcoma.

Ask the Experts: Waldenström Macroglobulinemia

Cancer Therapy Advisor asked 3 experts to weigh in on recommended treatment modalities for patients with Waldenström macroglobulinemia.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Latest Features

Lower-Dose, Shorter-Duration Chemotherapy Regimens: Is This a Trend?

Lower-Dose, Shorter-Duration Chemotherapy Regimens: Is This a Trend?

By

Lower doses and shorter treatment regimens have the potential to reduce both physical and financial toxicity for patients.

CD19 CAR T-Cell Therapies: "Expect an Evolution"

CD19 CAR T-Cell Therapies: "Expect an Evolution"

By

"CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses," according to Dr Michel Sadelin.

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

By

XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.

Does Epigenetic Therapy With Panobinostat Reduce CRPC Bicalutamide Resistance?

Does Epigenetic Therapy With Panobinostat Reduce CRPC Bicalutamide Resistance?

By

Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.

Nivolumab Monotherapy Provides Long-Term Benefit Advanced Melanoma

Nivolumab Monotherapy Provides Long-Term Benefit Advanced Melanoma

By

Dacarbazine, although once a staple of melanoma therapy, essentially has no current role in the treatment of any type or stage of melanoma.

more »

Editorial Advisory Board

 

Barbara Ann Burtness, MD

Steven Cohen, MD

E. David Crawford, MD

Isabel Cunningham, MD

Don S. Dizon, MD, FACP

Jeffrey M. Farma, MD

Neal D. Shore, MD, FACS

Mark A. Socinski, MD

Mario Sznol, MD

Click here for complete profiles

Fact Sheets

Obesity and Cancer

Obesity and Cancer

By
Differences in Treatment Site of Care: Why Is My Insurer Sending Me to a Particular Treatment Center?

Differences in Treatment Site of Care: Why Is My Insurer Sending Me to a Particular Treatment Center?

By
more »

Digital Issue



Flip through more digital issues

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs